Luo Li

List of Publications by Year
in descending order

19	225	1163117 8	1058476 14
papers	citations	h-index	g-index

21	21	21	372
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Identification of cross-reactive CD8+ T cell receptors with high functional avidity to a SARS-CoV-2 immunodominant epitope and its natural mutant variants. Genes and Diseases, 2022, 9, 216-229.	3.4	28
2	Long noncoding RNA HOTAIR regulates the invasion and metastasis of prostate cancer by targeting hepaCAM. British Journal of Cancer, 2021, 124, 247-258.	6.4	22
3	Systematic Evaluation for the Influences of the SOX17/Notch Receptor Family Members on Reversing Enzalutamide Resistance in Castration-Resistant Prostate Cancer Cells. Frontiers in Oncology, 2021, 11, 607291.	2.8	6
4	A Rapid and Efficient Screening System for Neutralizing Antibodies and Its Application for SARS-CoV-2. Frontiers in Immunology, 2021, 12, 653189.	4.8	20
5	p38 inhibition enhances TCR-T cell function and antagonizes the immunosuppressive activity of TGF-Î². International Immunopharmacology, 2021, 98, 107848.	3.8	5
6	Identification of the metabolic signatures of prostate cancer by mass spectrometryâ€based plasma and urine metabolomics analysis. Prostate, 2021, 81, 1320-1328.	2.3	10
7	Potent SARS-CoV-2 neutralizing antibodies with protective efficacy against newly emerged mutational variants. Nature Communications, 2021, 12, 6304.	12.8	42
8	T Cell Immunity Evaluation and Immunodominant Epitope T Cell Receptor Identification of Severe Acute Respiratory Syndrome Coronavirus 2 Spike Glycoprotein in COVID-19 Convalescent Patients. Frontiers in Cell and Developmental Biology, 2021, 9, 696662.	3.7	5
9	A Highly Conserved Peptide Vaccine Candidate Activates Both Humoral and Cellular Immunity Against SARS-CoV-2 Variant Strains. Frontiers in Immunology, 2021, 12, 789905.	4.8	7
10	PLCÎµ regulates metabolism and metastasis signalingÂvia HIFâ€1Î±/MEK/ERK pathway in prostate cancer. Journal of Cellular Physiology, 2020, 235, 8546-8557.	4.1	6
11	Inhibitor 9 Combined With Androgen Deprivation Therapy or Chemotherapy Delays the Malignant Behavior of Castration-Resistant Prostate Cancer Through K-Ras/PLCÎµ/PKCÎµ Signaling Pathway. Frontiers in Oncology, 2020, 10, 75.	2.8	1
12	PLCÎµ knockdown enhances the radiosensitivity of castrationâ€'resistant prostate cancer via the AR/PARP1/DNAâ€'PKcs axis. Oncology Reports, 2020, 43, 1397-1412.	2.6	1
13	PLCÎµ regulates prostate cancer mitochondrial oxidative metabolism and migration via upregulation of Twist1. Journal of Experimental and Clinical Cancer Research, 2019, 38, 337.	8.6	18
14	PLCÎµ knockdown overcomes drug resistance to androgen receptor antagonist in castrationâ€resistant prostate cancer by suppressing the wnt3a/Î²â€catenin pathway. Journal of Cellular Physiology, 2019, 234, 15472-15486.	4.1	6
15	Simvastatin delays castrationâ€'resistant prostate cancer metastasis and androgen receptor antagonist resistance by regulating the expression of caveolinâ€'1. International Journal of Oncology, 2019, 54, 2054-2068.	3.3	11
16	Combination of phospholipase CÎµ knockdown with GANT61 sensitizes castrationâ€'resistant prostate cancer cells to enzalutamide by suppressing the androgen receptor signaling pathway. Oncology Reports, 2019, 41, 2689-2702.	2.6	10
17	HepaCAM Regulates Warburg Effect of Renal Cell Carcinoma via HIF-1Î±/NF-ÎºB Signaling Pathway. Urology, 2019, 127, 61-67.	1.0	6
18	Phospholipase C (PLC)Îµ Promotes Androgen Receptor Antagonist Resistance via the Bone Morphogenetic Protein (BMP)-6/SMAD Axis in a Castration-Resistant Prostate Cancer Cell Line. Medical Science Monitor, 2019, 25, 4438-4449.	1.1	6

#	Article	IF	Citations
19	HepaCAM inhibits the malignant behavior of castration-resistant prostate cancer cells by downregulating Notch signaling and PF-3084014 (a Î³-secretase inhibitor) partly reverses the resistance of refractory prostate cancer to docetaxel and enzalutamide in vitro. International Journal of Oncology, 2018, 53, 99-112.	3.3	15